<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2CCB5A47-ADB6-4D56-A419-6E4F3D3BAF2B"><gtr:id>2CCB5A47-ADB6-4D56-A419-6E4F3D3BAF2B</gtr:id><gtr:name>Aarhus University Hospital</gtr:name><gtr:address><gtr:line1>Aarhus University Hospital</gtr:line1><gtr:line2>Aarhus University Hospital</gtr:line2><gtr:line3>Norrebrogade 44</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B80FA015-FF48-471E-839C-CB0CD2B7E9AD"><gtr:id>B80FA015-FF48-471E-839C-CB0CD2B7E9AD</gtr:id><gtr:name>Imanova</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Neuroimaging</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2CCB5A47-ADB6-4D56-A419-6E4F3D3BAF2B"><gtr:id>2CCB5A47-ADB6-4D56-A419-6E4F3D3BAF2B</gtr:id><gtr:name>Aarhus University Hospital</gtr:name><gtr:address><gtr:line1>Aarhus University Hospital</gtr:line1><gtr:line2>Aarhus University Hospital</gtr:line2><gtr:line3>Norrebrogade 44</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B80FA015-FF48-471E-839C-CB0CD2B7E9AD"><gtr:id>B80FA015-FF48-471E-839C-CB0CD2B7E9AD</gtr:id><gtr:name>Imanova</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/77B5A46C-7B57-46DD-91A6-EEBC4DB00D0D"><gtr:id>77B5A46C-7B57-46DD-91A6-EEBC4DB00D0D</gtr:id><gtr:firstName>Federico</gtr:firstName><gtr:otherNames>Edoardo</gtr:otherNames><gtr:surname>Turkheimer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0900891"><gtr:id>4A6C41FF-F2B7-4931-9C1C-53DA999169E1</gtr:id><gtr:title>Development of Quantitative PET Imaging Probes for Neuroinflammation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900891</gtr:grantReference><gtr:abstractText>Inflammation is a protective attempt by the immune response of the organism to remove the injurious stimuli as well as to initiate the healing process for the tissue. The inflammatory process is generally beneficial but an inflammation that runs unchecked can also lead to a host of diseases, such as hay fever, atherosclerosis, and rheumatoid arthritis. It is for this reason that inflammation is normally closely regulated by the body.
The brain and spinal cord are considered ?immune privileged? tissues in that they are separated from the rest of the body by a series of endothelial cells known as the blood-brain barrier, which prevent most infections from reaching the vulnerable nervous tissue. For this reason, inflammation in the CNS (Neuroinflammation) is mediated by a unique cell type, microglia. Microglia are part of the non-neuronal part of the cell population in the brain called glia, the other glial cell being the astrocytes and the oligodendrocytes. Quiescent microglia have a ramified morphology as they are constantly moving and analyzing the CNS for damaged neurons, plaques, and infectious agents; whenever an anomaly is detected, microglia enter an active state and undergo several morphological changes including the thickening and retraction of branches, the expression of immunomolecules, the secretion of cytotoxic factors, recruitment molecules and pro-inflammatory signaling molecules. 
Microglial activation is therefore present early in any pathological state of the brain and the in-vivo detection of microglial activation is a key diagnostic aim. Besides, microglia chronic activation has also been suggested as a key factor in the inception and/or progression of neurodegenerative diseases like Alzheimer?s disease and Parkinson?s disease. This project aims at delivering an optimal imaging biomarker for microglia using Positron Emission Tomography (PET) technology. PET is a Nuclear Medicine modality that is able to image the distribution of radioactive labelled compounds. The interest in imaging microglia with PET radiotracers is such that more than 50 radiotracers targeting microglia are now proposed world-wide. In the context of this training proposal, we will test the most promising PET microglia tracers, devise appropriate data-processing procedures and metrics that will allow the selection of the optimal marker to be used in the future in diagnostics, research and drug development.</gtr:abstractText><gtr:technicalSummary>The main aim of this research proposal is to shape a Post-Graduate Training Program in PET Methodology focused on the mathematical modelling of novel TSPO tracers in the normal and diseased brain. The TSPO is consistently expressed in the active microglia population in response to mild, acute or chronic brain injury. Microglia are the resident immuno-competent cell of the central nervous system and, in their active state, release pro-inflammatory molecules that initiate and sustain the immune response. This state is generally referred to as ?Neuroinflammation?. Microglia activity is not only regarded as the most sensitive marker of brain disease but it has also been proposed as pathogenic agent in neurodegenerative diseases, Alzheimer?s and Parkinson?s disease in particular. In-vivo TSPO imaging using PET started more than 20 years ago using 11C-PK11195, a positron emitter labelled antagonist for the TSPO but, because of the poor sensitivity of this tracer, research for novel TSPO tracers has surged in the last 5 years with more than 50 new PET TSPO-markers under various stages of clinical validation. It is because of this exceptionally large number of novel tracers and the importance of neuroinflammation for the clinical neurosciences that we define as the main objective of the proposed training program the identification of the optimal TSPO PET probe(s) and of the associated quantitative methodology.
The training program is proposed in three phases. The first one (3 months) will provide the trainee with the basic knowledge on PET methodology. The second phase, (21 months) will consist in a set of 3 months supervised research projects, that will look at various aspects(biological/pathology/chemical/kinetic) of novel TSPO ligands and supply data to a metric (the elaboration of which is one of the research questions) that will inform on the best amongst all candidates and on its quantification procedure. The last phase of the research program (24 months) will be carried out independently by the trainee in the field of TSPO data quantification and will make use of the wealth of clinical and pre-clinical data available at the participating PET centres. We believe that this proposal has unique strengths in the form and content of the training program, in the relevance of the theme for the neurosciences, in the quality and breadth of experience in PET Methodology of the proponents, and the strong academic/industrial partnership (Imperial/GSK) that characterizes the environment.</gtr:technicalSummary><gtr:fund><gtr:end>2014-06-15</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-06-21</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>632695</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Inflammation in pituitary tumour</gtr:description><gtr:id>1A0DEA0D-AB6F-4684-B389-05B27876701B</gtr:id><gtr:impact>In vivo TSPO expression has been evaluated in a small sample of subjects using 2nd generation TSPO PET tracer 11C-PBR28.</gtr:impact><gtr:partnerContribution>In vitro/ ex vivo experiments and in vivo PET scans</gtr:partnerContribution><gtr:piContribution>PET methodology development for investigating TSPO expression in pituitary gland for oncology</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imanova</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Inflammation in pituitary tumour</gtr:description><gtr:id>5C0593C5-408E-400C-BEFF-C230E7E8AE6F</gtr:id><gtr:impact>In vivo TSPO expression has been evaluated in a small sample of subjects using 2nd generation TSPO PET tracer 11C-PBR28.</gtr:impact><gtr:partnerContribution>In vitro/ ex vivo experiments and in vivo PET scans</gtr:partnerContribution><gtr:piContribution>PET methodology development for investigating TSPO expression in pituitary gland for oncology</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aarhus University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Aarhus Hospital</gtr:description><gtr:id>21E6DB1E-93A7-4F06-8439-B31DC86BE815</gtr:id><gtr:impact>In vivo PET data has been analysed to investigate the inflammation associated with spinal cord injury.
This is a multi-disciplinary collaboration as it covers area of medicine, neurology, imaging and quanfication.</gtr:impact><gtr:partnerContribution>Aarhus Hospital provided us clinical PET data of patients who has spinal cord injury;</gtr:partnerContribution><gtr:piContribution>We analysed the PET data using the SUPERPK approach developed by our team.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>PET Pharmacolkinetic Course 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>49C0F11A-2CC9-4517-9FB8-AE81769C5EF1</gtr:id><gtr:impact>50 students from academic institutions and pharmaceutical companies with different background(chemistry, biology, pharmacology, physics) attended the course, studied pharmacokinetics for PET imaging and performed computer exercises.

Students provide very good feedback of the lectures, exercises and discussion. The course benefits the students' understanding of the quantification of PET studies.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www2.kenes.com/brain2013/scientific/Pages/PET_Pharmacokinetics_Course.aspx</gtr:url><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Imaging MS Workshop</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DE9C99F3-41F6-48E4-B852-EE91A8DDBA31</gtr:id><gtr:impact>40 Attendees. Sparked joint research activities and joint grant applications.

Wider awareness of molecular imaging technology available for imaging Multiple Sclerosis in the UK</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1720000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Strategic Award: Neuroinflammation in Alzheimer's Disease and Depression</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>7EA7035F-92D7-472C-B27B-110E7875623D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Dementia (NIMA).</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>16536ED0-815A-49C6-93A1-EFAAE0E40C00</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>780500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Innovative Medicine Initiative (IMI)</gtr:description><gtr:end>2021-10-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>17A002CD-FFD1-4744-B20E-E32CA60FC232</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>459272</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New Investigator Research Grant</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>14B1A275-CD37-4BFD-9EE7-9883848E2583</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>in vivo PET scans using 11C-PBR28 with arterial blood samples</gtr:description><gtr:id>455BAEAB-54B8-474A-8D39-3710EFAE45A1</gtr:id><gtr:impact>The in vivo TSPO uptake is consistent with genetics</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>in vivo PET study with 11C-PBR28</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Different pharmacokinetic models have been applied in the analysis of in vivo PET data.</gtr:description><gtr:id>C3809002-A4DC-49CF-A150-A170529E9BEE</gtr:id><gtr:impact>Different models were used to quantify to TSPO binding in human brain in healthy volunteers and MS patients, and specifically the double input models identified the metabolite issues with tracers.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PK modelling</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>These PET scans were funded by GSK and performed by GSK and Imanova, which allows for the evaluation of different quantification methodology of TSPO imaging.</gtr:description><gtr:id>5AA95B83-C62D-4149-ADC7-BE6B5E918DD1</gtr:id><gtr:impact>These vivo imaging data is the first time in human data that TSPO/neuroinflammation that has been detected using 18F-PBR111. This tracer produced higher total signal than the traditional tracer 11C-PK11195. The in vivo uptake is consistent with genetics.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>in vivo PET scans wit 18F-PBR111</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A statistical modelling approach to estimate sample size required for longitudinal and disease characterisation studies using PET.</gtr:description><gtr:id>A65C57F2-A958-46AF-8A70-D9A5210514B7</gtr:id><gtr:impact>The methods have been used to assist in the experimental design of more than 8 in vivo PET studies on neuroinflammation.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Statistical tool for PET experimental design</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This modelling approach is developed to predict the in vivo performance of radioligands from in vitro/in silico data.</gtr:description><gtr:id>BF1C123F-0CB1-48EA-BAE9-27FBA97CAA5A</gtr:id><gtr:impact>This model assisted experimental design for TSPO imaging by estimating the in vivo reproducibility of the radioligand and the sample sizes/power required by the experiment.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Biomathematical modelling approach</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Imanova Ltd</gtr:companyName><gtr:description>Imanova is an innovative alliance between the UK's Medical Research Council and three world-class London Universities: Imperial College, Kings College and University College.

Established in April 2011 as an independent company, Imanova and its partners bring together a breadth and depth of knowledge and expertise that will drive research and innovation in imaging sciences. Imanova will have a real impact on human health and the understanding of disease.

Imanova now owns and manages the renowned Clinical Imaging Centre (CIC) located at Imperial College London's Hammersmith Hospital campus. This state of the art facility was developed by former owner GlaxoSmithKline, and has benefitted from &amp;pound;47million of investment in equipment and infrastructure since opening in 2007.</gtr:description><gtr:id>647924E5-4428-46FE-8D8D-0A8F8263A6C3</gtr:id><gtr:impact>Close collaboration on developing molecular imaging probes for neuroinflammation</gtr:impact><gtr:url>http://www.imanova.co.uk/</gtr:url><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ACEDCCEA-AFB0-414B-B387-29B7B8ACBBB5"><gtr:id>ACEDCCEA-AFB0-414B-B387-29B7B8ACBBB5</gtr:id><gtr:title>Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d97be839ee44a7633b43d8afe42e86ff"><gtr:id>d97be839ee44a7633b43d8afe42e86ff</gtr:id><gtr:otherNames>Guo Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D41EBD82-EA87-427B-AFFE-A1671B74B849"><gtr:id>D41EBD82-EA87-427B-AFFE-A1671B74B849</gtr:id><gtr:title>[&amp;sup1;&amp;sup1;C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0b305554ad541694efe530ad8e342b5"><gtr:id>d0b305554ad541694efe530ad8e342b5</gtr:id><gtr:otherNames>Su Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3BD34F3C-30D9-4796-BB7B-D6424AD7E05A"><gtr:id>3BD34F3C-30D9-4796-BB7B-D6424AD7E05A</gtr:id><gtr:title>TSPO expression in brain tumours: is TSPO a target for brain tumour imaging?</gtr:title><gtr:parentPublicationTitle>Clinical and translational imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a0a4019558b3f0706fd5c4ec285652b4"><gtr:id>a0a4019558b3f0706fd5c4ec285652b4</gtr:id><gtr:otherNames>Roncaroli F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2281-5872</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3ECC8529-E03D-4AFC-8E0E-0BB4D107A45D"><gtr:id>3ECC8529-E03D-4AFC-8E0E-0BB4D107A45D</gtr:id><gtr:title>Validation of an automatic reference region extraction for the quantification of [(18)F]DPA-714 in dynamic brain PET studies.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/84c146d83a811c37be9119e12fe9904d"><gtr:id>84c146d83a811c37be9119e12fe9904d</gtr:id><gtr:otherNames>Garc?a-Lorenzo D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3EBF901F-5103-4357-B334-CA89E517841D"><gtr:id>3EBF901F-5103-4357-B334-CA89E517841D</gtr:id><gtr:title>Quantification of the specific translocator protein signal of 18F-PBR111 in healthy humans: a genetic polymorphism effect on in vivo binding.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d97be839ee44a7633b43d8afe42e86ff"><gtr:id>d97be839ee44a7633b43d8afe42e86ff</gtr:id><gtr:otherNames>Guo Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7ED46320-2CB0-470B-9209-68F8E5FC9D0E"><gtr:id>7ED46320-2CB0-470B-9209-68F8E5FC9D0E</gtr:id><gtr:title>Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/003ef0c2090080af16a9718d5168846f"><gtr:id>003ef0c2090080af16a9718d5168846f</gtr:id><gtr:otherNames>Politis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EFD71901-214F-48A4-BB2E-230F344CE5AE"><gtr:id>EFD71901-214F-48A4-BB2E-230F344CE5AE</gtr:id><gtr:title>Kinetic modeling without accounting for the vascular component impairs the quantification of [(11)C]PBR28 brain PET data.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f7b3fc52c6cea6e41aeb69c25ad3e6f6"><gtr:id>f7b3fc52c6cea6e41aeb69c25ad3e6f6</gtr:id><gtr:otherNames>Rizzo G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E0E0D2AC-3D73-44F9-859D-1A82A95B6E0F"><gtr:id>E0E0D2AC-3D73-44F9-859D-1A82A95B6E0F</gtr:id><gtr:title>Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes.</gtr:title><gtr:parentPublicationTitle>Parkinsonism &amp; related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f9be49eefc2150e1f0bb017706484ad7"><gtr:id>f9be49eefc2150e1f0bb017706484ad7</gtr:id><gtr:otherNames>Kobylecki C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1353-8020</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D27ADC21-4584-4D3A-94A2-28441C5157F6"><gtr:id>D27ADC21-4584-4D3A-94A2-28441C5157F6</gtr:id><gtr:title>In vivo mapping of vascular inflammation using the translocator protein tracer 18F-FEDAA1106.</gtr:title><gtr:parentPublicationTitle>Molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4e0b450f1d5bc2b8d648f07ac17d789c"><gtr:id>4e0b450f1d5bc2b8d648f07ac17d789c</gtr:id><gtr:otherNames>Cuhlmann S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-3508</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DC7F2CD-0E10-48E9-A571-8CD08A164D3E"><gtr:id>8DC7F2CD-0E10-48E9-A571-8CD08A164D3E</gtr:id><gtr:title>A Variational Bayesian inference method for parametric imaging of PET data.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c3c8636226b48947e0b2752f552bbf0e"><gtr:id>c3c8636226b48947e0b2752f552bbf0e</gtr:id><gtr:otherNames>Castellaro M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F5B07752-70B8-4B1B-B632-4E1773B8F0F6"><gtr:id>F5B07752-70B8-4B1B-B632-4E1773B8F0F6</gtr:id><gtr:title>Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>EJNMMI research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ac6376c01f8d256d3c4f767c3a49715"><gtr:id>2ac6376c01f8d256d3c4f767c3a49715</gtr:id><gtr:otherNames>Nair A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99393CED-6E1C-4BDD-9876-87104075E318"><gtr:id>99393CED-6E1C-4BDD-9876-87104075E318</gtr:id><gtr:title>Response to Narendran and Frankle: The Interpretation of PET Microglial Imaging in Schizophrenia.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/75ca5ea61c140abe28a788ca8941849e"><gtr:id>75ca5ea61c140abe28a788ca8941849e</gtr:id><gtr:otherNames>Bloomfield PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/814427B3-A9D3-4D4D-AA7D-C1E392C9CF84"><gtr:id>814427B3-A9D3-4D4D-AA7D-C1E392C9CF84</gtr:id><gtr:title>Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9ed340a76e0a045e6532fee85138ebb1"><gtr:id>9ed340a76e0a045e6532fee85138ebb1</gtr:id><gtr:otherNames>Giannetti P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8CFC7A81-B290-4F08-8F75-D79A94D3566A"><gtr:id>8CFC7A81-B290-4F08-8F75-D79A94D3566A</gtr:id><gtr:title>A graphical method to compare the in vivo binding potential of PET radioligands in the absence of a reference region: application to [&amp;sup1;&amp;sup1;C]PBR28 and [&amp;sup1;8F]PBR111 for TSPO imaging.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d97be839ee44a7633b43d8afe42e86ff"><gtr:id>d97be839ee44a7633b43d8afe42e86ff</gtr:id><gtr:otherNames>Guo Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D176E0DD-2852-42C0-A21B-3A6D041AEDA6"><gtr:id>D176E0DD-2852-42C0-A21B-3A6D041AEDA6</gtr:id><gtr:title>Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f05d5c8816acacbd274481d87778e2e"><gtr:id>5f05d5c8816acacbd274481d87778e2e</gtr:id><gtr:otherNames>Edison P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900891</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>